#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Keith Kucinski Email
Chief Financial Officer . Matinas BioPharma
Bedminster, NJ
Locationk********@matinasbiopharma.com
Primary EmailHow to contact Keith Kucinski
Join and see Keith's contact info for free!Current Roles
Employees:
41Revenue:
$6.4MAbout
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, LYPDISO™ (MAT9001), for the treatment of cardiovascular and metabolic conditions. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling LYPDISO in a confirmatory head-to-head PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in the Q42020. In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas’ proprietary lipid nano-crystal (LNC) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.Matinas BioPharma Address
1545 Route 206 SouthBedminster, NJ
United States